

Amendment
Docket No. 2861-US-CNT2

Immunex Corporation

RECEIVED
CENTRAL FAX CENTERAmendments to the Claims

MAR 20 2007

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-17 (cancelled).

18 (currently amended). The substantially purified polypeptide of claim 30 31, wherein the polypeptide further comprises an Fc domain and/or a peptide linker.

Claims 19-21 (cancelled).

22 (withdrawn). An isolated polynucleotide encoding the polypeptide of claim 13.

23 (withdrawn). The polynucleotide of claim 22 comprising SEQ ID NO:1.

24 (withdrawn). An expression vector comprising the polynucleotide of claim 22.

25 (withdrawn). A recombinant host cell comprising the polynucleotide of claim 22.

26 (withdrawn). A host cell comprising the vector of claim 24.

27 (withdrawn). A method of expressing a polypeptide encoded by the polynucleotide of claim 22 comprising culturing a recombinant host cell into which the polynucleotide of claim 22 has been introduced.

28 (withdrawn). The method of claim 27 further comprising purifying the polypeptide.

Claims 29-30 (cancelled).

31 (new). A substantially purified adamalysin polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) amino acids 1 through 502 of SEQ ID NO:2;
- (b) amino acids 1 through 692 of SEQ ID NO:2;

Amendment
Docket No. 2861-US-CNT2

Immunex Corporation

- (c) amino acids 28 through 502 of SEQ ID NO:2;
- (d) amino acids 28 through 692 of SEQ ID NO:2;
- (e) amino acids 198 through 502 of SEQ ID NO:2; and
- (f) amino acids 198 through 692 of SEQ ID NO:2.

32 (new). A substantially purified polypeptide comprising amino acids 28 through 726 of SEQ ID NO:2.

33 (new). A substantially purified polypeptide comprising SEQ ID NO:2.

34 (new). A substantially purified polypeptide comprising SEQ ID NO:3.